Saturday, August 23, 2025

Medmen Posts Q4 Loss Of $46.2 Million

Medmen Enterprises (CSE: MMEN) last night reminded investors why Canaccord Genuity had a long standing $0.00 price target on the name. The firm reported its fourth quarter financial results, posting $42.0 million in revenue for the three month period, along with a net loss of $46.2 million.

Revenues were up 18.5% on a quarter over quarter basis, with the company pointing to Arizona as the reasoning for the improvement. Cost of goods sold meanwhile came in at $22.3 million, resulting in a gross profit of $19.7 million.

The firm however still can’t seem to get its operating expenses under control, reporting $41.4 million in expenses for the three month period. Expenses largely comprised of $33.5 million in selling, general and administrative expenses. Depreciation meanwhile amounted to a further $6.1 million in expenses, resulting in a total loss from operations of $21.7 million.

The loss was then further extended via $10.0 million in other expenses, as well as $10.0 million in interest expenses, leading to a total net loss of $46.2 million for the three month period.

For the full fiscal year, the firm posted revenues of $145.1 million, as well as a net loss of $157.6 million. Revenues were down 6.6% on an annual basis.

In terms of the balance sheet, the company was quick to highlight its total assets of $472.5 million as of year end, which includes $11.9 million in cash. The largest line item overall here is $137.8 million in property and equipment, followed by $115.4 million in intangible assets.

However, the company failed to identify at the same time that its liabilities currently total out at $726.1 million, meaning the firm currently has significant negative shareholder equity. Liabilities consists of liabilities for sale of $33.0 million, and other current liabilities of $142.7 million, as well as $191.1 million in notes payable, and $170.8 million in senior secured convertible credit facilities.

The firm has yet to post full financial results for the quarter.

As for Canaccord’s price target on the company, their analyst recently raised that target to $0.25 following the recent transactions conducted with Tilray (TSX: TLRY) and Serruya Private Equity.

Medmen Enterprises last traded at $0.40 on the CSE.


Information for this briefing was found via Sedar and MedMen Enterprises. The author has no affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

A Medical Breakthrough the Market Overlooked | David Elsley – Cardiol Therapeutics

Why Grade Beats Size in Silver Mining | Frank Basa – Nord Precious Metals

Are Investors Missing the Start of the Next Commodity Supercycle? | Morgan Lekstrom – NexMetals

Recommended

Emerita Resources Expands El Cura Drill Program By 10,000 Metres As Deposit Remains Open For Expansion

ESGold Signs MOU For Tailings Project In Colombia With Grades Up To 42 g/t Gold, 280 g/t Silver

Related News

Tilray: Analysts Leave Targets Unchanged After MedMen Investment

On August 17, Tilray (NASDAQ: TLRY) made the announcement that they formed a new limited...

Thursday, August 19, 2021, 01:03:00 PM

Is the End of the Line Near for MedMen?

It’s long been known by cannabis industry followers that MedMen Enterprises (CSE: MMEN) has a...

Tuesday, June 11, 2019, 07:30:12 AM

Tilray Imports Medical Cannabis to USA to Assist Research on Breast Cancer Related Disorder

Tilray Inc (NASDAQ: TLRY) announced this morning that it has successfully imported medical cannabis from...

Thursday, October 24, 2019, 09:15:29 AM

Medmen Posts Revenues of $43.9 Million, Net Loss of $82.6 Million For First Quarter

Medmen Enterprises (CSE: MMEN) filed its first quarter 2020 financials these evening, revealing revenues of...

Tuesday, November 26, 2019, 05:02:41 PM

Tilray Sees Revenue Decline To $144.1 Million In Q2 2023

Tilray Brands (TSX: TLRY) appears to be struggling when it comes to topline revenue. The...

Monday, January 9, 2023, 08:29:13 AM